Biosimilar Development insights

  1. Lonza and Atvio Biotech Seek New Technologies To Advance Personalized Medicine
    5/25/2017

    Despite their potential to increase the efficiency of the healthcare system, autologous cell therapy treatments present significant challenges to most companies when it comes to development and manufacturing. Innovators across the industry who want to see personalized medicine, such as autologous cell therapies, reach its full potential are focusing on developing technology that can create a realistic business model for these treatments.

  2. Will Asia Go Big In Biosimilars Adoption And Manufacturing?
    5/18/2017

    Since 1984 when U.S. regulations favoring adoption of generics were enacted, the global generics market has grown to account for roughly 38% of global pharmaceutical spending and this portion is expected to increase to 43% in the next five years.1 Will biosimilars follow the generics trajectory in the next few decades?

  3. Biosimilars Producer, Alvotech, Finds Opportunities In Iceland
    5/11/2017

    In June 2016, Alvotech opened their new biosimilar manufacturing facility in Reykjavik, Iceland, using best of breed solutions from leading Life Science vendors.  The key directive for Alvotech was to create a flexible, agile process which could adapt and be used for any conceivable process.  The result:  A high yield disposable fermentation and downstream process, with a fill-and-finish line for vials and prefilled syringes, tied together with a complete, end-to-end upstream/downstream automation and Manufacturing Execution System. 

  4. Single-Use Solutions For Cell Culture Scale-Up And Technology Transfer
    5/11/2017

    A question and answer session with Barbara Paldus, Ph.D., Vice President and General Manager Finesse, part of Thermo Fisher Scientific

  5. Bioburden Sources You Might Have Missed
    5/3/2017

    A problem with traditional mAb manufacturing is that there are so many potential entry points for microbial contamination. There are, however, ways to shut the door on contamination.

  6. Cost And Impact Of A Bioburden Incident
    5/3/2017

    Manufacturing biologicals is tricky. A major concern is the risk of microbial contamination, jeopardizing product safety and causing high costs. But there are solutions for decreasing the risks.

  7. Evolve With Flexibility: Advancing Single-Use Technology With Industry Collaboration
    4/27/2017

    GE Healthcare has compiled this ebook, which includes information on some of the latest SUT trends in the world of bioprocessing.

  8. Capitalize On A Merger/Acquisition: 4 Tips To Consolidate Your CMO Network
    4/27/2017

    Complex CMO networks are expensive and require many resources to manage. Plus, they prevent purchasing and operating at scale. Yet, the process of consolidating CMOs is daunting.

  9. Beyond Immune Checkpoint Inhibitors To A New Era Of Personalized Medicine
    4/27/2017

    Immunotherapies are being touted—both in scientific literature and the general media—as the most promising advances in cancer treatment in decades.

  10. A DoE Approach To Liquid-Liquid Mixing
    4/10/2017

    This application note describes mixing and heating-cooling characterization data for the Xcellerex XDM/ XDUO 500 single-use mixer. A design of experiments (DoE) approach to liquid-liquid mixing was successfully applied to establish a statistical model to predict the mixing time throughout the working range.